What are the unique challenges in biosimilar process development?

Biosimilar development targets analytical similarity to reference product without access to originator process. Challenges: reverse-engineering quality attributes from characterization of reference (multiple lots for variability), achieving similar CQAs using different cell lines and processes, navigating reference product variability (establishing acceptance ranges), and limited room for optimization (constrained by similarity requirements). Process considerations: cell line selection for desired glycosylation capabilities, media/feed optimization for quality matching not just productivity, process parameters tuned to quality attributes, and analytical method development for comprehensive characterization. Regulatory requirements (FDA, EMA) emphasize totality of evidence across analytical, functional, and clinical studies. Continuous reference product monitoring accommodates changes over product lifecycle. Success requires deep analytical capabilities and flexible manufacturing platforms.